Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Rallybio Corp (RLYB)

Rallybio Stockholders Approve Avenzo Merger Share Issuance and Reverse Split

Neutral Impact 5 of 5 m&a Written later

At its November 4, 2026 annual meeting, Rallybio stockholders approved the issuance of Rallybio common stock to Avenzo securityholders under the May 31, 2026 merger agreement, a share issuance the filing says will result in a change of control. Stockholders also approved a reverse stock split at a ratio of 1-for-2 to 1-for-9, a name change to Avenzo Therapeutics, Inc., and an increase in authorized shares. The filing says the board will be reconstituted upon completion of the merger.

Key points

  • Share issuance to Avenzo securityholders approved with 4,506,703 votes for, 15,979 against, 14 abstaining and 267,624 broker non-votes.
  • Reverse split ratio range of 1-for-2 to 1-for-9 approved; final ratio to be mutually determined by Rallybio and Avenzo.
  • Authorized common shares to increase from 200,000,000 to 500,000,000; name change to Avenzo Therapeutics, Inc. approved.
  • Avenzo 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan approved, both effective only upon completion of the merger.

The filing

CompanyRallybio Corp (RLYB)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:58 PM ET
Accession number0001193125-26-447550

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.